Bio-Path (BPTH) Stock Price, News & Analysis

Company Overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Key Stats

• Today's Range: $0.16 to $0.17
• 50-Day Range: $0.14 to $0.22
• 52-Week Range: $0.12 to $3.39
• Volume: 14,362 shs
• Average Volume: 992,531 shs
• Market Capitalization: $1.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Bio-Path Stock Analysis - MarketRank™

Bio-Path scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Bio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bio-Path has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bio-Path are expected to grow in the coming year, from ($3.34) to ($1.55) per share.

Price to Book Value per Share Ratio

Bio-Path has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.81% of the float of Bio-Path has been sold short.

Short Interest Ratio / Days to Cover

Bio-Path has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Path has recently decreased by 5.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bio-Path does not currently pay a dividend.

Dividend Growth

Bio-Path does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.81% of the float of Bio-Path has been sold short.

Short Interest Ratio / Days to Cover

Bio-Path has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Path has recently decreased by 5.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for BPTH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Path insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.72% of the stock of Bio-Path is held by insiders.

Percentage Held by Institutions

Only 5.74% of the stock of Bio-Path is held by institutions.

BPTH Stock Analysis - Frequently Asked Questions

How have BPTH shares performed this year?

Bio-Path's stock was trading at $1.16 at the beginning of the year. Since then, BPTH shares have decreased by 86.2% and is now trading at $0.1605.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its quarterly earnings data on Thursday, August, 15th. The company reported ($1.16) EPS for the quarter, beating analysts' consensus estimates of ($1.54) by $0.38.
Read the conference call transcript.

When did Bio-Path's stock split?

Bio-Path's stock reverse split before market open on Friday, February 23rd 2024.The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), Micron Technology (MU), Anavex Life Sciences (AVXL) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 7/07/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPTH
• CIK: 1133818
• Web: www.biopathholdings.com
• Phone: (832) 742-1357
• Fax: N/A
• Employees: 10
• Year Founded: 2007

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +11,609.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,842.40%
• Return on Assets: -337.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 8,308,000
• Free Float: 5,726,000
• Market Cap: $1.42 million
• Optionable: Optionable
• Beta: -0.03